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Abstract
Q-Secretase is an enzymatic activity responsible for the final cleavage of the amyloid precursor protein leading to the
production of the amyloid L-peptide (AL). Q-Secretase is likely an aspartyl protease, since its activity can be inhibited by both
pepstatin and active-site directed aspartyl protease inhibitors. Recent work has indicated that presenilins 1 and 2 may
actually be the Q-secretase enzymes. Presenilin (PS) mutations, which lead to an increase in the production of a longer form of
AL, are also the most common cause of familial Alzheimer’s disease (FAD). Therefore, in an attempt to better characterize
the substrate preferences of Q-secretase, we performed experiments to determine how FAD-linked mutations in PS1 would
affect the generation of AL peptides from full length precursor substrates that we have previously demonstrated to be
proteolytically cleaved at alternative sites and/or by enzymatic activities that are pharmacologically distinct. Presenilin
mutations increased the production of AL peptides from sites distal to the primary cleavage site (‘longer’ peptides) and in
several cases also decreased production of ‘shorter’ peptides. These results support a model in which the FAD-linked mutants
subtly alter the conformation of the Q-secretase complex to favor the production of long AL. ß 2002 Elsevier Science B.V.
All rights reserved.
Keywords: Alzheimer’s disease; Amyloid L-peptide; Amyloid precursor protein; Mass spectrometry; Presenilin 1; Q-Secretase
1. Introduction
The amyloid L-peptide (AL), the principle compo-
nent of the senile plaques characteristic of Alzheim-
er’s disease (AD), is a normally secreted proteolytic
product of the L-amyloid precursor protein (APP)
[1,2]. AL is generated from APP by two sequential
proteolytic events: an initial cleavage to produce the
AL amino terminus (L-secretase [3^6]) followed by
another endoproteolytic cleavage of the resulting
fragment to create the carboxyl terminus (Q-secretase
[7,8]). Although the identity of Q-secretase has not
de¢nitively been established, recent work has
strongly indicated that presenilin (PS) 1, mutations
of which are the most frequent cause of familial AD
(FAD) [9,10], may actually be the catalytic subunit
of a larger protein complex responsible for Q-secre-
tase catalyzed cleavages [11^13].
Q-Secretase is an unusual enzymatic activity, and is
interesting for several reasons. First, the cleavage site
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of the substrate(s) is predicted to lie within the trans-
membrane domain (TMD), making it a member of a
new class of proteases involved in regulated intra-
membranous proteolysis (RIP) [14]. In one of the
better studied cases of RIP involving processing of
the sterol regulatory element binding protein, cleav-
age may not actually take place within the mem-
brane. In this case, cleavage appears to occur near
the cytosolic face after the protein undergoes a par-
tial unwinding of the K-helical TMD following a
cleavage event on the lumenal side [15]. In the case
of APP, the position of the Q-cleavage site with re-
spect to the membrane appears to be the prime de-
terminant of cleavage, and could also take place at
the cytoplasm/membrane junction in a similar ‘cut-
expose-cut’ fashion [16] or within the transmembrane
domain itself. Second, C-terminal fragments (CTF)
of APP are not the only substrate for Q-secretase
activity, as the Notch intracellular domain is also
released by a PS1 dependent, Q-secretase-like cleavage
at residues near the cytoplasm/membrane junction,
an event necessary for Notch signaling [17^19].
Therefore, Q-secretase is not only an unusual proteo-
lytic activity and a major therapeutic target for the
treatment of AD, but also has important additional
biological consequences.
Although the weight of available evidence sup-
ports the notion that presenilin(s) and Q-secretase
are one and the same, there are still unanswered
questions. Presenilins have also been shown to be
involved in the regulation of intracellular tra⁄cking
[20], and display complex interactions with a growing
list of important cellular proteins including the cat-
enins [21^24], Bcl-X-L [25], GSK3L [26], rab GDP
dissociation inhibitor [27], E-cadherin [28], and may
have functional roles in the cellular unfolded protein
response [29,30] and calcium signaling [31]. How PS’s
role as a protease can be reconciled with this bewil-
dering array of protein interactions is unclear,
although one recently isolated protein, Nicastrin, ap-
pears to have a direct role in the production of AL
[32]. Though it has been suggested that one of the
major problems with PS as Q-secretase(s) is the ap-
parent discrepancy between the predominantly endo-
plasmic reticulum localization of the PSs and the site
of the majority of Q-secretase activity in the more
distal secretory pathway (Golgi) and endosomal sys-
tem [33], several recent studies suggest that the CTF
substrates and PSs are co-localized in high molecular
weight complexes that may exist in lipid raft micro-
domains. Third, studies with a variety of inhibitor
compounds have indicated di¡erential inhibition of
the Q40 and Q42 activities [16,34^37]. It is possible to
greatly inhibit AL40 production while having little
e¡ect on AL42 [38], and robust di¡erential inhibition
can also be obtained in a cell-free assay system elim-
inating the possibility that these e¡ects are due to
incomplete cell penetrance [39]. Together, these re-
sults indicate that there is likely to be more than
one Q-secretase activity. Whether this means the ex-
istence of more than one enzyme or the same enzyme
in di¡erent functional conformations is not yet
known.
Using a set of APP transmembrane domain mu-
tants known to be cleaved by pharmacologically dis-
tinct Q-secretase activities [16], we have recently dem-
onstrated that dominant negative PS mutants that
reduce Q-secretase activity do so regardless of
whether or not a particular cleavage site is sensitive
or insensitive to a given inhibitor compound [38]. To
gain insight into how FAD-linked mutations increase
AL42 production, we performed a similar set of ex-
periments whereby the e¡ect of FAD-linked PS1 mu-
tants on APP TMD mutant processing was exam-
ined. These studies reveal that these FAD-linked
PS1 mutants appear to act in a sequence independent
fashion to shift cleavage to favor production of long
AL peptides, sometimes at the expense of shorter AL
species. These ¢ndings favor a model wherein PS
mutations alter conformation of the Q-secretase com-
plex in a manner that enhances preference for distal
over proximal cleavage events.
2. Materials and methods
2.1. Materials
Oligonucleotide primers were obtained from Inte-
grated DNA Technologies (IDT, IA, USA). Molec-
ular biology supplies for PCR and restriction digests,
tissue culture media and reagents were from Gibco
BRL (Rockville, MD, USA). FuGene 6 transfection
reagent and the protease inhibitor cocktail were from
Roche (Indianapolis, IN, USA). Commercial anti-
bodies were from Takeda Industries (BA27, BC05,
BBADIS 62081 10-4-02 Cyaan Magenta Geel Zwart
M.P. Murphy et al. / Biochimica et Biophysica Acta 1586 (2002) 199^209200
and BAN50; Tokyo, Japan) and Senetek (Maryland
Heights, MO, USA). All other materials were from
Sigma (St. Louis, MO, USA).
2.2. cDNA constructs
Presenilin 1 mutants were constructed by generat-
ing two PCR fragments from wild type PS1 cDNA.
A forward primer was used to generate a HindIII site
at the 5P end of PS1 and a speci¢c reverse primer
from the actual site of mutation, which also created
a BsmBI class IIa restriction site; this is removed by
the restriction enzyme to leave the ¢nal sequence
unaltered except for the desired mutation. A similar
strategy was used to generate the 3P end of the
cDNA, terminating in a BamHI site. After comple-
tion of the restriction digests, the pieces were as-
sembled by triple ligation in the pAG3hyg vector
[16]. For these studies we chose representatives of
two categories of APP TMD mutants: point muta-
tions at the Q-site or insertion/deletion mutants
deigned to shift the position of the Q-site relative to
the membrane (Fig. 1). Three of these mutants
(I637P, ins625^628 and del625^628) act to dramati-
cally shift the pro¢le of the AL species generated; all
four exhibit signi¢cantly reduced sensitivity to phar-
macological inhibition of total AL production
(I637P6 ins625^6286del625^6286wild type APP).
Also, speci¢c cleavages in each mutant are di¡eren-
tially sensitive. For example, AL42 production in the
T639K mutant is completely resistant to pepstatin
inhibition. All PS1 FAD (A285V, E280G and
M139V) and APP mutations were veri¢ed by se-
quencing (all primer sequences are available on re-
quest). All APP mutations were made on an
APP695vNL background to maximize the amount
of AL secreted for mass spectrometry. Therefore,
transfection with APP695vNL without mutations in
the primary AL sequence was used to generate con-
trol AL values.
2.3. Tissue culture
To generate pooled stable lines, 70% con£uent six-
well plates of Chinese hamster ovary (CHO) cells
were transfected overnight with 1 Wg of plasmid
DNA with 3 Wl of FuGene 6 in serum-free Opti-
MEM. This was replaced by Ham’s F12 supple-
mented with 10% fetal bovine serum and 800 Wg/ml
of hygromycin B. After 10^14 days, selection was
reduced by 75%. After initial evaluation, expression
levels were periodically monitored by immunoblot-
ting throughout the course of the experiment, and
the cell lines have been subsequently maintained for
multiple passages. Transient transfections were per-
formed in an identical manner, albeit without hy-
gromycin selection. All cell lines were maintained at
37‡C under 5% CO2.
2.4. AL and APP analyses
AL was analyzed by sandwich ELISA and immu-
noprecipitation/mass spectrometry (IP/MS) as previ-
ously described [16,38]. Brie£y, serum-free medium
samples (1.0 ml/35 mm well) were collected following
overnight conditioning and complete protease inhib-
itor cocktail added. Total AL concentration was
measured by 3160/4G8 sandwich ELISA and, where
possible, AL40 and AL42 were measured by 3160/
BA27 and 3160/BC05 ELISA, respectively. All ELI-
SA measurements were performed 2^4 times per
sample per assay. Conditioned medium was also im-
munoprecipitated with 4G8/protein-A/G-plus aga-
rose beads and subjected to matrix-assisted laser de-
sorption/ionization time-of-£ight (MALDI-TOF)
mass spectrometric analysis as described [16,40].
Mass spectra were averaged from at least 500 mea-
Fig. 1. Diagram detailing the APP TMD mutants used in this
study. APP695vNL is shown at the top, along with the L-secre-
tase cleavage site (N-terminal to AL1) and the area of the most
common Q-secretase cleavages (the major Q-site for each APP is
shown by the gray arrow). The normal AL region (up to AL42)
is indicated in bold italics. The location of the point mutations
in I637P and T639K are shown with diamonds. The duplicated
region is underlined in the insertion mutant, and the site of de-
letion indicated with an arrowhead. All four mutants are shown
to illustrate how the sequences are predicted to align relative to
the normal Q-secretase site.
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surements, using bovine insulin as an internal mass
calibrant. Synthetic AL12ÿ28 peptide was added to
each sample (10 nM) as an internal positive control.
Total secreted sAPP was measured in the same
conditioned medium samples using an Ab207 com-
petitive ELISA [16]. For analysis of full length APP
and PS1 expression, cells were lysed in ice-cold 1%
Triton X-100/Tris-bu¡ered saline (TBS; pH 8.0)
+PIC and insoluble material separated by a 2 min
centrifugation at 20 000Ug. Lysates (10^15 Wg total
protein, by BCA assay) were separated on 10^20%
Tris-Tricine gels, transferred to PVDF membranes,
blocked overnight with 5% non-fat dried milk/TBS
(pH 7.4)/0.05% Tween 20, and immunoblotted. PS1
was visualized with rabbit anti-PS1 loop and/or anti-
PS1-N antibodies (each at 1/1000 dilution) [38,41].
For APP, blots were probed with anti-CT20 anti-
body (1/500 dilution) [16,38].
2.5. AL numbering
To avoid confusion due to the TMD inserts and
deletions, AL numbering in this paper refers to the
true amino acid length of the AL peptide produced.
For example, in del625^628, the major AL peptide
fragment is 39 amino acids long (AL39), but the car-
boxyl terminus is actually the threonine at position
43 relative to the wild type AL sequence. The terms
long and short AL are used to refer to AL peptides
longer and shorter than the major AL peptide pro-
duced, respectively; proximal and distal are relative
to the lumenal membrane.
3. Results
We examined the e¡ect of the PS1 FAD-linked
mutants E280G, M139V and A285V on processing
of a variety of APP TMD mutants. APP TMD mu-
tants were transiently transfected into pooled stable
lines overexpressing either FAD-linked PS1 mutants
or PS1wt (Fig. 2). Transient overexpression of APP
was nearly identical in these cell lines, as monitored
both by Western blot and sAPP in the conditioned
medium (not shown).
AL production was analyzed both by ELISA and
IP/MS. APP695vNL transfection into these PS1 mu-
tants lines resulted in a selective increase in AL42 as
quantitated both by ELISA and IP/MS. The x-fold
increase in percent AL1ÿ42 relative to PS1wt for
E280G, M139V, and A285V lines was 1.8, 3, and
1.8, respectively (as determined by ELISA; not
shown); similar results were obtained for IP/MS. Im-
munoprecipitation/mass spectrometric analyses also
demonstrated that FAD-linked PS1 mutants also
shift cleavage of the APP TMD mutants to favor
production of longer forms of AL (Fig. 3). In each
of the TMD mutants, at least one AL fragment lon-
ger than the major cleavage fragment was produced
at increased levels (Fig. 4). Interestingly, in some
cases, AL peptides shorter than the major cleavage
fragment were correspondingly reduced (cf. Section
2.5).
3.1. Point mutations (I637P and T639K)
The APP TMD mutants I637P and T639K exhibit
reduced sensitivity to inhibition by both pepstatin
[16] and peptide aldehyde inhibitors [38]. In the
case of T639K (where the cleavage at the 42 site is
almost completely insensitive to pharmacological in-
hibition), this occurs even in the absence of any dis-
cernible alteration in the AL MS pro¢le. However,
for the I637P mutant, the decrease in pharmacolog-
ical sensitivity is also accompanied by a major shift
in cleavage site utilization away from the principal 40
site towards both 37 and 43.
Expression of these APP mutants on a background
of FAD-linked PS1 mutations resulted in a signi¢-
cant increase in AL42 production relative to the ma-
Fig. 2. Immunoblot (anti-PS1-N antibody) showing expression
of PS1 in pooled stable CHO cell lines. Overexpression can be
seen by the detection of the full length PS1 holoprotein, which
is clearly visible in each of the wild type (PS1wt) and mutant
cell lines in contrast to untransfected controls (3).
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jor AL species generated, as determined by IP/MS
(AL37 for I637P and AL40 for T639K; Fig. 4C and
D, respectively). For I637P, a large increase was also
apparent in the relative amount of AL43 produced in
two of the three FAD-linked PS1 mutants tested
(E280G and A285V). In the T639K mutant, the use
of proximal cleavage sites 37^39 was also reduced to
some extent, although this did not attain statistical
signi¢cance for this mutant (F3;12 = 2.73, P6 0.13).
3.2. Insertion and deletion mutants (ins625^628 and
del625^628)
Although these APP mutants are slightly less sen-
Fig. 3. Mass spectra of AL peptides resulting from IP/MS analysis. AL peptide pro¢le from cells stably expressing either human PS1
wild type (A^E) or PS1 with the FAD-linked E280G point mutation (F^J). Cells were transiently transfected with APP695vNL (A,F),
I637P (B,G), T639K (C,H), ins625^628 (D,I) or del625^628 (E,J). AL number used re£ects true peptide length. Peaks corresponding
to mouse AL sequence are labeled with ‘m’ and peaks without identi¢cation are labeled as ‘n’.
BBADIS 62081 10-4-02 Cyaan Magenta Geel Zwart
M.P. Murphy et al. / Biochimica et Biophysica Acta 1586 (2002) 199^209 203
sitive to inhibition, the primary feature of interest is
the cleavage shift observed. In the mutants used for
this study, four amino acids were either inserted
(ins625^628, by duplication of the adjacent GAII
region) or removed (del625^628; GAII deleted)
from the APP transmembrane domain. The net e¡ect
is to induce utilization of relatively proximal or distal
cleavage sites, respectively, while maintaining the
length of the major AL species at 37^40 amino acids,
thus supporting a spatially constrained model of Q-
secretase activity [16]. For example, del625^628 has a
‘shorter’ transmembrane domain, resulting in the uti-
lization of C-terminal cleavage sites that are distal to
the lumenal membrane; the principal cleavage site in
this case is after the threonine at position 43 of the
wild type AL sequence instead of the valine at posi-
tion 40. This results in an AL peptide with an altered
carboxyl terminus with a length of 39 amino acids
(after correcting for the deleted amino acids). Con-
versely, ins625^628 has a ‘longer’ TMD and is cut
using more proximal cleavage sites (e.g. the glycine at
the AL33 position), but the principle AL peptides are
37^38 amino acids long (Fig. 3D,E).
Similar to the point mutations, in an FAD-linked
PS1 background the insertion and deletion mutants
also display an increase in the relative amount of at
least one longer form of AL. In the ¢rst case, ins625^
628 produces primarily more AL41, but to a lesser
extent more AL42 also (Fig. 4E). For del625^628,
the longer fragment produced was AL41 (Fig. 4F).
Like T639K, peptides shorter than the major AL
species were also reduced in the del625^628 mutant,
although in this case the reduction was statistically
signi¢cant (F3;12 = 5.154, P6 0.02). Interestingly,
AL38, which corresponds in primary amino acid se-
quence to the normal Q42 carboxyl terminus, was sig-
ni¢cantly (Dunnett’s test, P6 0.03) reduced in the
FAD-linked mutants.
4. Discussion
Mutations in APP that either change cleavage site
utilization and/or sensitivity to pharmacological inhi-
bition still show relative elevations in longer forms of
AL when expressed in an FAD-linked PS1 back-
ground. The shift towards longer forms of AL in
all cases occurs irrespective of whether the activity
generating that cleavage is sensitive or insensitive
(e.g. AL42 in T639K; Fig. 3D) to inhibition by either
the classic aspartyl protease inhibitor pepstatin [16]
or peptide aldehyde inhibitors [38]. This ¢nding has
potentially important implications for models of Q-
secretase function.
There was some indication that the increased pro-
duction of longer AL species was also accompanied
by a corresponding reduction in shorter AL species.
This was most pronounced in the del625^628 mu-
tant, but was also evident to a lesser extent with
other forms of APP. For example, in cell lines trans-
fected with APP695vNL, AL37 cleavage is decreased
by all three FAD-linked mutants, and in lines trans-
fected with T639K, AL37, AL38, and AL39 are all
decreased. The other TMD mutants examined either
did not have any AL fragments shorter than the ma-
jor peptide (I637P) or the absolute level of shorter
peptides was extremely low (AL36 from ins625^628),
possibly explaining why no decrease was detected.
Since AL42 is nearly always expressed relative to
AL40, this e¡ect is di⁄cult to detect other than by
the IP/MS method reported in this study.
A shift in cleavage preference towards longer
C
Fig. 4. (A) Longer forms of AL are increased relative to the major proteolytic fragment in di¡erent APP TMD mutants. At least one
fragment with a C-terminus distal to the primary cleavage site was consistently elevated in each mutant (F3;20 = 15.846, P6 0.001; the
e¡ect of each PS1 FAD mutant was signi¢cant (P6 0.05, Dunnett’s test)). Fragments shown (major AL/‘longer’ AL) : 695vNL, 40/42;
ins625^628, 37/41; del625^628, 39/41; I637P, 37/42; T639K, 40/42. (B^F) The major peak elevated in the FAD-linked PS1 mutants is
marked with an asterisk, as determined from mass spectra based on approx. 500 measurements, and the results shown are averaged
from two independent experiments. (B) Principal AL species derived from APP harboring the normal Q-secretase site. (C) I637P; AL42
is consistently increased in all three FAD mutants; AL43 is also markedly elevated in E280G and A285V (arrowheads). (D) T639K;
AL42 is elevated. (E) ins625^628; AL41 and, to a lesser extent, AL42, are elevated. (F) del625^628; AL41 is increased. Interestingly, all
three of the AL cleavages N-terminal to the major cleavage site are signi¢cantly reduced in this TMD mutant (P6 0.02); note AL38
(arrow, P6 0.03), which would correspond to a peptide derived from the normal Q42 cleavage site.
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forms of AL at the expense of shorter forms is sup-
portive of the idea that the FAD-linked PS1 muta-
tions actually lead to a partial decrease in normal
function (the production of AL40 by a ‘Q40’ activity).
Indeed, given the large number (60+) of known
FAD-linked mutations in PS1, the increase in long
AL is unlikely to be through a strict gain of function
mechanism. In fact, it has recently been demon-
strated that a sel12 (a Caenorhabditis elegans PS1
homologue) loss-of-function mutation (C60S) leads
to increased AL42 when the analogous mutation
(C92S) is introduced into PS1 [42]. Similarly, FAD-
linked PS1 mutants may act as a loss-of-function
mutation with regard to Notch proteolytic cleavage
[43,44].
Earlier results have suggested that Q-secretase may
Fig. 5. Schematic of the spatially constrained model of separate Q40 (blue arrows) and Q42 (purple arrows) activities outlined in this pa-
per. The ins625^628 and del625^628 mutants are shown, along with wild type APP (WT), to illustrate this point. The AL region is
shown as the dark green box (positions of amino acids in the WT AL sequence, the aspartate at position 1 and the alanine at position
42, border the box as indicated), with the inserted/deleted region shown as the light green area close to the lumenal face of the trans-
membrane domain. As can be seen from the diagram, the Q40 and Q42 activities produce shorter and longer AL peptides, respectively,
regardless of the amino acids present at the cleavage site. It is these longer peptides in general that are increased in the case of FAD-
linked PS1 mutations.
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cleave APP CTF substrates a ¢xed distance from the
lumenal or extracellular membrane [16], and this
study also indicates that the Q40 and Q42 enzymatic
activities may be spatially distinct. In other words,
a loss of Q40 activity brought about by mutations in
PS1 leads to an increase in available substrate for the
Q42 activity. The del625^628 APP mutant is the best
illustration of this concept. In this mutation, the
shorter TMD places the amino acid normally at po-
sition 43 relative to the wild type AL sequence in
position to be cleaved by a spatially constrained Q40
activity, resulting in a peptide 39 amino acids long.
The more distal 45 cleavage site (relative to wild type
AL) is now likewise positioned for cleavage by a Q42
activity, which produces a 41 amino acid long pep-
tide. When the del625^628 mutant is expressed on an
FAD-linked PS1 background, the result is an in-
crease in the 41 amino acid peptide (generated by
the Q42 activity) and a reduction in the shorter AL
species. Importantly, one of the AL species reduced is
a 38 amino acid peptide which corresponds to the
normal AL42 carboxyl terminus, illustrating that
even Q42 activity is not dependent on primary amino
acid sequence (Fig. 5).
These results favor a model of Q-secretase function
in which the overproduction of longer forms of AL
in PS1 FAD mutants is dependent on factors (e.g.
altered substrate positioning relative to the active
site) other than a speci¢c increase in AL42 generating
activity per se. This notion is also supported by the
di¡erential pharmacological inhibition of shorter and
longer AL species in the insert and deletion mutants.
For example, use of an AL40 selective inhibitor re-
duces the production of shorter AL peptides (e.g.
AL38 in del625^628) and increases the production
of longer peptides (such as AL41) ; in the ins625^
628 form of APP, short AL peptides are also sup-
pressed by the same compound, whereas AL40 is ac-
tually increased [38]. Similar results are also obtained
following treatment with pepstatin [16], although
these studies have not yet been performed on a PS1
FAD mutant background. This change in pharmaco-
logical sensitivity can also be explained as above, by
substrate positioning relative to the active site of Q-
secretase, with the added stipulation that the Q40 ac-
tivity is more sensitive to these types of inhibitors
than the Q42 activity.
Taken together, these ¢ndings indicate that the Q40
and Q42 activities are likely to be spatially, as well as
pharmacologically, distinguishable. Since knockout
of PS1 reduces both AL40 and AL42 and PS2 has
no e¡ect on AL production when knocked out alone
[45,46], the parsimonious scenario that, for example,
PS1 is responsible for the Q40 activity and PS2 for the
Q42 activity seems unlikely. Therefore, if PSs are the
elusive Q-secretase enzymes, they most likely exist in
at least two conformations, Q40 and Q42, with the as-
sumption of the Q42 conformation favored by the
FAD-linked mutations.
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